They include antibody inhibitors blocking EphA2 in esophageal and gastric cancer [61], antibody blockers against EphA3 in hematologic malignancies [62], protein complex blockers against EFNB2 in solid and hematologic cancers [63], and an EFNA4 monoclonal antibody conjugate, the ADC (antibody–drug conjugate) drug PF-06647263 [64]. This evidence concerns the gene EPHA3 and gastric cancer.